We are a trusted partner to health authorities and payers as we help optimise the use of limited healthcare budgets by delivering quality care with a patient-centred focus. Our aim is to develop sustainable, long-term solutions that put the patient in the centre.
The demographic change with an ageing population, an increase in chronic disease, patients having higher expectations on healthcare delivery and the pressure on public finances are challenging healthcare systems around the world. Decision makers and payers need partners that co-create solutions together with them and that have a holistic view on the patient, not only on their specific area of expertise. Especially for chronic kidney diseases, where patients suffer from up to 20 co-morbidities, the healthcare systems need solutions that combine cost efficiency with a strong focus on the patient and deliver value.
Diaverum can add that value from day one – through how the kidney centres are organised and equipped, how we manage the different treatment modalities and treatment times, how we introduce quality measurement scores and other measures and how much we focus on our patients. This is where Diaverum is special: an independent service provider, focusing on care only. The organisation is patient-centric; it is built around the patients and the people who care for them. And we have a proven expertise in partnering with the public sector to optimise renal care delivery.
Payers and authorities may benefit from Diaverum setting up structured initiatives to reduce vascular catheter rates. Haemodialysis treatments with artero-venous fistulas or grafts as opposed to vascular catheters result in improved quality of life, with less hospitalisation and a lower morbidity and mortality. When acquiring a new kidney center, Diaverum uses a structured approach and investments to reduce vascular catheter rates, which in turn reduces hospitalisation days gradually, meaning better quality of life for the patients and lower costs for the healthcare systems. By coordinating care, we are able to achieve excellent medical performances and outcomes, with better buying conditions and less overhead costs. With outcome-based measures, we are securing transparency. In addition, the more localised delivery of care reduces transportation costs. All in all, more patients treated by Diaverum means a reduced total expenditure.